The Southern African HIV Clinicians Society supports evidence-based law- and policy-making. We believe that South Africa will not reach our own, as well as international, HIV reduction and treatment targets or related public health goals if it does not decriminalise adult sex work.
The Society welcomes the new guidelines which recommend ART for all people living with HIV and PrEP for all individuals at high risk of contracting HIV.
The second annual national stock outs survey, conducted over the fourth quarter of 2014, comprises of the most comprehensive data on the frequency, prevalence and impact of stock outs to date.
Following the announcement by the Minister of Health, Hon Dr Aaron Motsoaledi, that South Africa will increase the CD4 threshold for antiretroviral therapy to 500 in January 2015. Prof Graeme Meintjes, on behalf of the Society's Adult ART guideline committee, outlines the Society’s position on ART initiation in patients with a CD4 count between 350-500
The Society notes the positive impacts arising from the case of the Mississippi baby, despite the disappointment felt at the news that the child now has a detectable viral load.
A guide for clinicians and programme managers on how to switch from 3 separate antiretroviral (ARV) drugs to the new, single, fixed-dose combination (FDC) tablet containing tenofovir (TDF), emtricitabine (FTC) and efavirenz (EFV).
An urgent matter regarding access to healthcare, particularly HIV care, has arisen in Gauteng. The TAC has responded with the following letter. The main aim of the letter is to request an urgent meeting on this matter.
Society response to WHO's guideline threshold of 500 cells/ul for the initiation of ART in asymptomatic, non-pregnant adults.
This letter regarding the ‘Regulations Relating to Research on Human Subjects’ was submitted to the Department of Health on Monday 29 July 2013 and was endorsed by a number of organisations.
The Society does not recommend the routine use of EFV in children under the age of 3 years or less than 10kg due to efficacy and toxicity concerns.
This is a letter from the South African HIV Clinicians Society to public sector clinicians regarding private sector patients transferring in on the FDC tablets, including the approach and management to be taken to introducing FDC treatment.
This letter is from the Southern African HIV Clinicians Society to clinicians in the private sector regarding the prescribing of FDC tablets to public sector patients including the approach and management for phasing in the FDC treatment.
In wake of latest trial results, the CDC stresses that consistent use is imperative when using Pre-Exposure Prophylaxis to prevent HIV infection. This statement can be attributed to Jonathan Mermin, M.D., Director of CDC’s Division of HIV/AIDS Prevention
The Microbicide Trials Network released the following results of a major HIV prevention trial, known as the VOICE trial. The results suggest that daily use of a product – whether a vaginal gel or an oral tablet – does not appear to be the right approach for preventing HIV in young, unmarried African women.
The Microbicide Trials Network (MTN) prepared the following document to aid in understanding the results of the VOICE trial.
The U.S. Women and PrEP Working Group, a coalition of more than 50 women from leading AIDS and women’s health organizations, released the following document in response to the results of the VOICE trial.
Child and adolescent committee of SAHIV Clinicians Society made the following statement regarding the announcement of the first documented case of a child cured of HIV that took place at the 2013 Conference on Retroviruses and Opportunistic Infections (CROI) in Atlanta on March 4 2013.